Boston Scientific Bids for BTG

Sunday, 25th November 2018

The big is a significant premium over BTG’s current price. At the time the bid was announced, BTG’s closing share price was 615p per share, and the bid was a 51 percent premium over the 90 day average share price. BTG plans to recommend the deal to shareholders, stating that it considers the terms of the acquisition to be both fair and reasonable. The news of the bid boosted share prices in the short term.

Boston Scientific chief executive Michael F. Mahoney said that the acquisition of BTG and its portfolio of peripheral inventions is an exciting move and something that they see as an extension of their own category leadership strategy. The plan is that it will augment the company’s capabilities in areas where they currently are unable to meet needs, such as pulmonary embolisms and cancer.

BTG makes a number of medical technology devices, as well as medications and antidotes, and has some interesting specializations including making antidotes against snake venom. Mahoney is confident that adding those devices and drugs to their portfolio will help to rapidly advance their capabilities with regard to patient care, by allowing them to enjoy strong synergies and also offering better return on investment for the company’s investors.

Share Search
Share Search Share Search

Visit the Share Search.
Share Search

Share News
Share News will do their best to ensure the quality of the information displayed on this site, but all information is provided as-is, free of charge. We cannot be held responsible for any loss, material or otherwise, due to incorrect information found here. UK data supplied by NBTrader and Digital Look. Share Prices are at least 15 minutes delayed.